Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director · President and Head of R&D | July 10, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Taysha Gene Therapies, Inc.
Report date July 10, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,410 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Sale · Disposed 200,000 · Balance 936,410 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 3,800 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.47 · Expires 2025-09-14 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 178,494 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.61 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 37,750 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.24 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 25,200 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Performance Stock Units (Right to Buy)SEC Table II · derivative / convertible security · Expires 2028-05-15 | Direct | 9,906 |
Reported balance
After 2018-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-15 · Grant · Acquired 9,906 · Balance 9,906 F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied. F5: Immediately exercisable. |
| Performance Stock Units (Right to Buy)SEC Table II · derivative / convertible security · Expires 2028-05-15 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-15 · Disposition to issuer · Disposed 9,906 · Balance 0 F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied. F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F6: Pursuant to the Merger Agreement, each outstanding PSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock subject to the PSU. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied.
F5: Immediately exercisable.
F6: Pursuant to the Merger Agreement, each outstanding PSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock subject to the PSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2017 Filed Sep 5, 2017 17:22 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-051431 · doc4.xml · derivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,174 Underlying: Common Stock · 1,780 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 17:22 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 574 | $93.91 | $53,904.34 |
DisclosureSEC source: 0001209191-17-051431 · doc4.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.60 to $94.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 17:22 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,206 | $92.93 | $112,073.58 |
DisclosureSEC source: 0001209191-17-051431 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.46 to $93.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 17:22 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,780 | $18.47 | $32,876.60 |
DisclosureSEC source: 0001209191-17-051431 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:02 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-047420 · doc4.xml · derivative · entry 5 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,954 Underlying: Common Stock · 1,780 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:02 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 17 | $92.75 | $1,576.75 |
DisclosureSEC source: 0001209191-17-047420 · doc4.xml · nonDerivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:02 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 696 | $91.92 | $63,976.32 |
DisclosureSEC source: 0001209191-17-047420 · doc4.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.68 to $92.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:02 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,067 | $91.24 | $97,353.08 |
DisclosureSEC source: 0001209191-17-047420 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.67 to $91.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:02 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,780 | $18.47 | $32,876.60 |
DisclosureSEC source: 0001209191-17-047420 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 18:05 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-043569 · doc4.xml · derivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,734 Underlying: Common Stock · 1,780 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 18:05 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 299 | $82.28 | $24,601.72 |
DisclosureSEC source: 0001209191-17-043569 · doc4.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.16 to $82.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 18:05 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,481 | $81.80 | $121,145.80 |
DisclosureSEC source: 0001209191-17-043569 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.15 to $82.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 18:05 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,780 | $18.47 | $32,876.60 |
DisclosureSEC source: 0001209191-17-043569 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-037268 · doc4.xml · derivative · entry 5 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,514 Underlying: Common Stock · 1,780 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:33 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 170 | $71.91 | $12,224.70 |
DisclosureSEC source: 0001209191-17-037268 · doc4.xml · nonDerivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.69 to $72.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:33 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 977 | $71.19 | $69,552.63 |
DisclosureSEC source: 0001209191-17-037268 · doc4.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.66 to $71.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:33 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 633 | $70.20 | $44,436.60 |
DisclosureSEC source: 0001209191-17-037268 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.59 to $70.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,780 | $18.47 | $32,876.60 |
DisclosureSEC source: 0001209191-17-037268 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 18:24 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,200 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-17-032146 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2027-05-10 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on May 10, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on June 10, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:59 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-029252 · doc4.xml · derivative · entry 5 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,294 Underlying: Common Stock · 1,780 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:59 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 22 | $82.58 | $1,816.76 |
DisclosureSEC source: 0001209191-17-029252 · doc4.xml · nonDerivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:59 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 576 | $81.91 | $47,180.16 |
DisclosureSEC source: 0001209191-17-029252 · doc4.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.53 to $82.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:59 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,182 | $81.11 | $95,872.02 |
DisclosureSEC source: 0001209191-17-029252 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.52 to $81.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:59 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,780 | $18.47 | $32,876.60 |
DisclosureSEC source: 0001209191-17-029252 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:16 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,781 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-17-025752 · doc4.xml · derivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,074 Underlying: Common Stock · 1,781 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:16 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,781 | $76.13 | $135,587.53 |
DisclosureSEC source: 0001209191-17-025752 · doc4.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.71 to $76.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:16 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 1,781 | $18.47 | $32,895.07 |
DisclosureSEC source: 0001209191-17-025752 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.